This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
This report describes the occurrence of invasive bacterial diseases (IBD) in Europe during 2012, based on data collected through The European Surveillance System (TESSy).
This report presents the epidemiological situation for vaccine-preventable diseases – invasive bacterial diseases (invasive Haemophilus influenzae, meningococcal and pneumococcal disease) as of 2012 and describes the statistical and epidemiological methods used.
The Annual Epidemiological Report 2014 gives an overview of the epidemiology of communicable diseases of public health significance in Europe, drawn from surveillance information on the 52 communicable diseases and health issues for which surveillance is mandatory in the European Union and European Economic Area countries.
This report presents the outcomes of a technical workshop, organised by ECDC, to seek a consensus on a common strategy to reduce the public health burden caused by pertussis in the EU/EEA countries.
In May 2012 a collection of five strains of Haemophilus spp was sent to 28 participating reference laboratories in the IBD-labnet surveillance network for quality assurance testing. The laboratories were asked to characterise the five strains by performing standard laboratory protocols for the methods usually used by the laboratory for: species identification, biotyping and serotyping by serological methods and/or PCR.
The results of this EQA are published in the this report.
The results of this external quality assurance distribution have shown that European Haemophilus reference laboratories differ in the level of characterisation of strains, ranging from simple speciation to full identification and typing. All but two laboratories routinely phenotypically serotype isolates. Fifteen laboratories (52%) performed PCR-based capsular genotyping, 23 laboratories (79%) reported antimicrobial susceptibility testing results.